POLB 001 patent portfolio strengthened through granting of US patent
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Poolbeg Pharma PLC (AIM:POLB) Strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Poolbeg Pharma PLC (AIM:POLB) Positive Initial Data Analysis in POLB 001 Trial
Early data readout indicates a successful LPS human challenge trial
Poolbeg Pharma PLC (AIM:POLB) identifies novel RSV drug candidates
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Poolbeg Pharma PLC (AIM:POLB) Metabolic diseases oral delivery licence signed
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS human challenge trial completed
POLB 001 LPS human challenge clinical trial successfully completed
Poolbeg Pharma PLC (AIM:POLB) Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023
Poolbeg Pharma PLC (AIM:POLB) Capital Markets Day
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it
Poolbeg Pharma PLC (AIM:POLB) Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine Platform
Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund
Poolbeg Pharma PLC (AIM:POLB) Commencement of trading on US OTCQB market
Poolbeg Pharma commences trading on OTCQB Market in the United States